Invention Application
- Patent Title: AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT
-
Application No.: US17046199Application Date: 2019-04-10
-
Publication No.: US20210070869A1Publication Date: 2021-03-11
- Inventor: Maarten JANMAAT , Esther BREIJ , Ulf FORSSMANN , Tahamtan AHMADI , Julia BOSHUIZEN , Daniel PEEPER , Nora PENCHEVA
- Applicant: GENMAB A/S
- Applicant Address: DK Copenhagen V
- Assignee: GENMAB A/S
- Current Assignee: GENMAB A/S
- Current Assignee Address: DK Copenhagen V
- International Application: PCT/EP2019/059171 WO 20190410
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K47/68 ; A61P35/00
Abstract:
The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.
Information query
